.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,972,990

« Back to Dashboard

Claims for Patent: 5,972,990

Title: Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims
Abstract:The invention involves a method for treating a human survivor of a heart attack and provides further improvement in survival following the heart attack by the early initiation and long-term administration of a renin-angiotensin system inhibitor, preferably an angiotensin converting enzyme inhibitor. The inhibitor may be used on its own, or in conjunction with other therapeutic compounds such as data blockers and thrombolytic agents. The preferred inhibitor is captopril.
Inventor(s): Pfeffer; Marc A. (Chestnut Hill, MA), Pfeffer; Janice M. (Chestnut Hill, MA), Braunwald; Eugene (Weston, MA)
Assignee: Brigham and Women's Hospital, Inc. (Boston, MA)
Application Number:07/981,196
Patent Claims: 1. A method for treating a human survivor of a myocardial infarction who is free of hypertension and congestive heart failure and is otherwise free of indications for angiotensin II inhibition treatment to prevent repeat myocardial infarction and to increase the likelihood of survival following the myocardial infarction comprising:

administering to the human survivor who is free of hypertension and congestive heart failure and is otherwise free of indications for angiotensin II inhibition treatment a therapeutically effective amount of an angiotensin II inhibitors wherein the human survivor has a left ventricular ejection fraction of less than or equal to 40% after the myocardial infarction.

2. A method for treating a human survivor of a myocardial infarction as claimed in claim 1 wherein the inhibitor is an angiotensin II antagonist.

3. A method as claimed in claim 2 wherein the angiotensin II antagonist is Losartan (2-N-butyl-4-chloro-5-hydoxmethyl-1-[(2'-1H-tetrazol-5-yl)biphenyl-4-yl methyl]imadazole.

4. A method as claimed in claim 1, wherein the angiotensin II inhibitor is a peptide.

5. A method as claimed in claim 1, wherein the angiotensin II inhibitor is administered for an extended period of time.

6. A method as claimed in claim 1, wherein the angiotensin II inhibitor is administered to the human survivor within 16 days of the myocardial infarction.

7. A method as claimed in claim 1, wherein the angiotensin II inhibitor is administered to the human survivor only after three days have passed since the myocardial infarction.

8. A method as claimed in claim 1, wherein the angiotensin II inhibitor is administered to the human survivor within 16 days of the myocardial infarction, but only after 3 days have passed since the myocardial infarction, and wherein the angiotensin II inhibitor is administered for an extended period of time to the survivor.

9. A method as claimed in claim 1, wherein the angiotensin II inhibitor is administered at the maximum dose tolerable.

10. A method as claimed in any one of claims 5, 6, 7, 8 and 9, wherein the angiotensin II inhibitor is an angiotensin II antagonist.

11. A method as claimed in claim 10, wherein the angiotensin II antagonist is a peptide.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc